Suspension of Execution for Cancellation of Hugel Botulinum Toxin Product Approval

[Asia Economy Reporter Seo So-jeong] Botulinum toxin company Hugel announced on the 17th that its request for a suspension of execution regarding the 'cancellation of product approval, etc.' filed with the Seoul Administrative Court has been granted.

Earlier, the Ministry of Food and Drug Safety (MFDS) stated that Hugel sold botulinum toxin products domestically without national batch release approval and announced the cancellation of the product approval as of the 13th of this month.

In response, Hugel filed a complaint for cancellation of the product approval cancellation, a request for suspension of execution, and a request for provisional disposition with the Seoul Administrative Court on the same day, initiating legal action against the head of the Seoul Regional Food and Drug Administration.

According to the court's decision, the administrative disposition imposed on Hugel by the MFDS will be suspended until the 30th day from the date of the judgment in the lawsuit filed by Hugel against the Seoul Food and Drug Administration for the cancellation of the product approval cancellation.

In a statement, Hugel said, "The products subject to the MFDS disposition were export drugs produced and sold for export purposes and are not subject to national batch release approval."

This content was produced with the assistance of AI translation services.